Effect of a newly developed ketolide antibiotic, telithromycin, on metabolism of theophylline and expression of cytochrome P450 in rats

Life Sciences

Volumn 79, Issue 1, 2006, Pages 50-56

  Nosaka, Hiroyuki ^a   Nadai, Masayuki ^b   Kato, Miki ^b   Yasui, Kazumasa ^b   Yoshizumi, Hideo ^b   Miyoshi, Mika ^a   Zhao, Ying Lan ^c,d   Baba, Kenji ^c   Takagi, Kenzo ^a   Hasegawa, Takaaki ^c  

^a NAGOYA UNIVERSITY   (Japan)

^b MEIJO UNIVERSITY   (Japan)

^c AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SICHUAN UNIVERSITY   (China)

Author keywords

Cytochrome P450 1A2 (CYP1A2); Cytochrome P450 3A2 (CYP3A2); Drug interaction; Telithromycin; Theophylline

Indexed keywords

1 METHYLURIC ACID; 1,3 DIMETHYLURIC ACID; CYTOCHROME P450 1A2; CYTOCHROME P450 3A2; CYTOCHROME P450 3A4; DRUG METABOLITE; ETHOXYRESORUFIN DEETHYLASE; KETOLIDE; LIVER ENZYME; TELITHROMYCIN; THEOPHYLLINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG MEGADOSE; DRUG METABOLISM; ENZYME ACTIVITY; EXAMINATION; HYDROXYLATION; INJECTION; KIDNEY CLEARANCE; LIVER LEVEL; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BLOTTING, WESTERN; BRONCHODILATOR AGENTS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; KETOLIDES; MALE; MEMBRANE PROTEINS; MICROSOMES, LIVER; RATS; RATS, SPRAGUE-DAWLEY; THEOPHYLLINE;

EID: 33646510497     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2005.12.022     Document Type: Article

References (38)

1. Burke M.D., Thompson S., Weaver R.J., Wolf C.R., and Mayer R.T. Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochemical Pharmacology 48 5 (1994) 923-936
2. Campbell M.E., Grant D.M., Inaba T., and Kalow W. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metabolism and Disposition 15 2 (1987) 237-249
3. Dresser G.K., Spence J.D., and Bailey D.G. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clinical Pharmacokinetics 38 1 (2000) 41-57
4. Gorski J.C., Jones D.R., Haehner-Daniels B.D., Hamman M.A., O'Mara E.M., and Hall S.D. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clinical Pharmacology and Therapeutics 64 2 (1998) 133-143
5. Grygiel J.J., Miners J.O., Drew R., and Birkett D.J. Differential effects of cimetidine on theophylline metabolic pathways. European Journal of Clinical Pharmacology 26 3 (1984) 335-340
6. Gu L., Gonzalez F.J., Kalow W., and Tang B.K. Biotransformation of caffeine paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 2 2 (1992) 73-77
7. Haghgoo S., Hasegawa T., Nadai M., Wang L., Ishigaki T., Miyamoto K., and Nabeshima T. Brain distribution characteristics of xanthine derivatives and relation to their locomotor activity in mice. Journal of Pharmacy and Pharmacology 47 5 (1995) 412-419
8. Hasegawa T., Nadai M., Kuzuya T., Muraoka I., Apichartpichean R., Takagi K., and Miyamoto K. The possible mechanism of interaction between xanthines and quinolone. Journal of Pharmacy and Pharmacology 42 11 (1990) 767-772
9. Hasegawa T., Kuzuya T., Apichartpichean R., Nadai M., Nitta A., Takagi K., and Nabeshima T. Structure-related inhibitory effect of quinolones on alkyl-xanthine elimination in rats. Pharmacology and Toxicology 69 1 (1991) 5-8
10. Hasegawa T., Nadai M., Haghgoo S., Yamaki K., Takagi K., and Nabeshima T. Influence of a newly developed quinolone, T-3761, on pharmacokinetics of theophylline in rats. Antimicrobial Agents and Chemotherapy 39 9 (1995) 2138-2140
11. Jackson J.E., Powell J.R., Wandell M., Bentley J., and Dorr R. Cimetidine decreases theophylline clearance. American Review of Respiratory Disease 123 6 (1981) 615-617
12. Jonkman J.H., and Upton R.A. Pharmacokinetic drug interactions with theophylline. Clinical Pharmacokinetics 9 4 (1984) 309-334
13. Kitaichi K., Nakayama H., Ueyama J., Nadai M., Baba K., Takagi K., Takagi K., Ohta M., and Hasegawa T. Down-regulation of cytochrome P450 proteins and its activities by Shiga-like toxin II from Escherichia coli O157 : H7. Biochemical Pharmacology 67 8 (2004) 1427-1435
14. Kuzuya T., Takagi K., Apichartpichean R., Muraoka I., Nadai M., and Hasegawa T. Kinetic interaction between theophylline and a newly developed quinolone, NY-198. Journal of Pharmacobio-Dynamics 12 7 (1989) 405-409
15. Ledirac N., de Sousa G., Fontaine F., Agouridas C., Gugenheim J., Lorenzon G., and Rahmani R. Effects of macrolide antibiotics on CYP3A expression in human and rat hepatocytes: interspecies differences in response to troleandomycin. Drug Metabolism and Disposition 28 12 (2000) 1391-1393
16. Lohmann S.M., and Miech R.P. Theophylline metabolism by the rat liver microsomal system. Journal of Pharmacology and Experimental Therapeutics 196 1 (1976) 213-225
17. Marquis J.F., Carruther S.G., Spence J.D., Brownstone Y.S., and Toogood J.H. Phenytoin-theophylline interaction. New England Journal of Medicine 307 19 (1982) 1189-1190
18. Matsunaga N., Hayashi M., Yamamoto K., Nishijima T., Kizu J., Nishihara K., Takanaka A., Morikawa A., and Nakashima E. Simultaneous assessment of the in vivo amount of CYP1A2 and CYP3A2 by the PKCYP-test using theophylline in rats. Drug Metabolism and Pharmacokinetics 17 3 (2002) 190-198
19. Miyoshi M., Nadai M., Nitta A., Ueyama J., Shimizu A., Takagi K., Nabeshima T., Takagi K., Saito K., and Hasegawa T. Role of tumor necrosis factor-alpha in down-regulation of hepatic cytochrome P450 and P-glycoprotein by endotoxin. European Journal of Pharmacology 507 1-3 (2005) 229-237
20. Nadai M., Hasegawa T., Kuzuya T., Muraoka I., Takagi K., and Yoshizumi H. Effects of enoxacin on renal and metabolic clearance of theophylline in rats. Antimicrobial Agents and Chemotherapy 34 9 (1990) 1739-1743
21. Nakura H., Tateishi T., Watanabe M., Asoh M., Tanaka M., Kumai T., and Kobayashi S. Effect of hypoalbuminemia on the disposition of theophylline. Comparative study with Sprague-Dawley rats and a mutant Sprague-Dawley hyperlipidemic strain with hypoalbuminemia. Drug Metabolism and Disposition 26 6 (1998) 595-597
22. Ogura Y., Hasegawa T., Yokochi Y., Yamada S., Kitazawa S., and Takagi K. Clinical application of substrate-labeled fluorescent immunoassay with antiserum produced using 9-theophylline-BSA immunogen. Japanese Journal of Hospital Pharmacy 9 3 (1983) 260-266
23. Omura T., and Sato R. The carbon monoxide-binding pigment of liver microsomes. Journal of Biological Chemistry 239 7 (1964) 2370-2378
24. Periti P., Mazzei T., Mini E., and Novelli A. Pharmacokinetic drug interactions of macrolides. Clinical Pharmacokinetics 23 2 (1992) 106-131
25. Principi N., and Esposito S. Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients. Drug Safety 20 1 (1999) 25-41
26. Purdon M.P., and Lehman-McKeeman L.D. Improved high-performance liquid chromatographic procedure for the separation and quantification of hydroxytestosterone metabolites. Journal of Pharmacology and Toxicological Methods 37 2 (1997) 67-73
27. Rogge M.C., Solomon W.R., Sedman A.J., Welling P.G., Toothaker R.D., and Wagner J.G. The theophylline enoxacin interaction. I. Effect of enoxacin dose size on theophylline disposition. Clinical Pharmacology and Therapeutics 44 5 (1988) 587-597
28. Sarkar M.A., Hunt C., Guzelian P.S., and Karnes H.T. Characterization of human liver cytochromes P-450 involved in theophylline metabolism. Drug Metabolism and Disposition 20 1 (1992) 31-37
29. Shi J., Montay G., Leroy B., and Bhargava V.O. Effects of itraconazole or grapefruit juice on the pharmacokinetics of telithromycin. Pharmacotherapy 25 1 (2005) 42-51
30. Sugie M., Asakura E., Zhao Y.L., Torita S., Nadai M., Baba K., Kitaichi K., Takagi K., Takagi K., and Hasegawa T. Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. Antimicrobial Agents and Chemotherapy 48 3 (2004) 809-814
31. Takagi K., Hasegawa T., Ogura Y., Suzuki R., Yamaki K., Watanabe T., Kitazawa S., and Satake T. Comparative studies on interaction between theophylline and quinolones. Journal of Asthma 25 2 (1988) 63-71
32. Takagi K., Yamaki K., Nadai M., Kuzuya T., and Hasegawa T. Effect of a new quinolone, sparfloxacin, on the pharmacokinetics of theophylline in asthmatic patients. Antimicrobial Agents and Chemotherapy 35 6 (1991) 1137-1141
33. Ueyama J., Kitaichi K., Nadai M., Iwase M., Tomyo N., Kanazawa H., Suzuki R., Takagi K., Takagi K., and Hasegawa T. Effects of pioglitazone on endotoxin-induced decreases in hepatic drug-metabolizing enzyme activity and expression of CYP3A2 and CYP2C11. European Journal of Pharmacology 498 1-3 (2004) 257-265
34. Ueyama J., Nadai M., Kanazawa H., Iwase M., Nakayama H., Hashimoto K., Yokoi T., Baba K., Takagi K., Takagi K., and Hasegawa T. Endotoxin from various gram-negative bacteria has differential effects on function of hepatic cytochrome P450 and drug transporters. European Journal of Pharmacology 510 1-2 (2005) 127-134
35. Wijnands W.J.A., Vree T.B., and van Herwaarden C.L.A. Enoxacin decreases the clearance of theophylline in man. British Journal of Clinical Pharmacology 20 6 (1985) 583-588
36. Williams J.F., Lowitt S., and Szentivanyi A. Effects of Phenobarbital and 3-methylcholanthrene pretreatment on the plasma half-life and urinary excretion profile of theophylline and its metabolites in rats. Biochemical Pharmacology 28 19 (1979) 2935-2940
37. Yamaguchi S., Zhao Y.L., Nadai M., Yoshizumi H., Cen X., Torita S., Takagi K., Takagi K., and Hasegawa T. Involvement of the drug transporters P-glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrobial Agents and Chemotherapy 50 1 (2006) 80-87
38. Zhou S., Yung Chan S., Cher Goh B., Chan E., Duan W., Huang M., and McLeod H.L. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clinical Pharmacokinetics 44 3 (2005) 279-304